Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 20, 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
November 12, 2024 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024 07:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...
U.S. Myelodysplastic Syndromes (MDS) Patient Insights Report: HCP Treatment Discussions, Treatment Satisfaction & Awareness, Clinical Trial Interest, and Much More
September 26, 2024 04:20 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndromes (MDS) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
September 12, 2024 07:00 ET
|
Biosplice Therapeutics, Inc.
Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024 16:01 ET
|
Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
July 01, 2024 08:05 ET
|
Senti Biosciences, Inc.
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
‘Like a hand fitting into a glove’: Purdue-engineered compound designed to treat drug-resistant acute myeloid leukemia
June 20, 2024 10:55 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., June 20, 2024 (GLOBE NEWSWIRE) -- Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute...
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024 09:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...